Immunic Reveals Promising Data for Vidofludimus Calcium at MSToronto2026

Immunic AG presented new data for vidofludimus calcium at the 10th Joint ACTRIMS-ECTRIMS Meeting, focusing on multiple sclerosis (MS) treatment. Their findings highlighted positive outcomes from the Phase 2 CALLIPER trial, emphasizing the drug's durability in disability outcomes and consistent safety profile. The company's research also explored Nurr1-dependent neuronal survival and neuroprotective effects, extending beyond DHODH inhibition.

Additionally, exploratory analyses linked reduced EBV-specific T-Cell signatures with improved cognitive performance in MS patients, reinforcing the drug's potential. The company introduced novel disability measures showing vidofludimus calcium's superiority over placebo in progressive MS patients. These findings align with Immunic's plans to proceed with Phase 3 trials, anticipating results by the end of 2026.